|
 |
|
|||||||
|
|||||||||
Eur Respir J 2007, doi:10.1183/09031936.00162006
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLE |
Impact of statins and ACE inhibitors on mortality for subjects hospitalized with pneumonia
1 VERDICT/South Texas Veterans Health Care System; and Divisions of General Internal Medicine
2 VERDICT/South Texas Veterans Health Care System; and Psychiatry, University of Texas Health Science Center at San Antonio
3 VERDICT/South Texas Veterans Health Care System; and Pulmonary and Critical Care Medicine
4 VERDICT/South Texas Veterans Health Care System
5 Pulmonary and Critical Care Medicine
* To whom correspondence should be addressed. E-mail: mortensene{at}uthscsa.edu.
 |
Abstract |
|---|
Recent studies suggest that statins and ACE inhibitors may have beneficial effects for some types of infections. The purpose of our study was to examine the association of outpatient use of these medications on 30-day mortality for subjects >65 years of age hospitalized with community-acquired pneumonia.
We conducted a retrospective national cohort study conducted using Department of Veterans Affairs administrative data including subjects 
65 years of age hospitalized with community-acquired pneumonia, and having at least one year of prior Veterans Affairs outpatient care.
We identified 8652 subjects with a mean age of 75 years, 98.6% were male, and 9.9% of subjects died within 30-days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio 0.54, 95% confidence interval 0.42–0.70) and ACE inhibitor use (0.80, 0.68–0.89) were significantly associated with decreased 30-day mortality.
Use of statins and ACE inhibitors prior to admission is associated with decreased mortality in subjects hospitalized with community-acquired pneumonia. Randomized controlled trials are needed to examine whether the use of these medications in patients hospitalized with community-acquired pneumonia may be beneficial.
Keywords: Angiotensin-converting enzyme inhibitor, HMG-CoA reductase inhibitor, mortality, pneumonia
This article has been cited by other articles:
|
|
 |
|
  V. Chopra and S. A. Flanders Does Statin Use Improve Pneumonia Outcomes? Chest, November 1, 2009; 136(5): 1381 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R P Young, R Hopkins, and T E Eaton Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence Postgrad. Med. J., August 1, 2009; 85(1006): 414 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dublin, M. L Jackson, J. C Nelson, N. S Weiss, E. B Larson, and L. A Jackson Statin use and risk of community acquired pneumonia in older people: population based case-control study BMJ, June 16, 2009; 338(jun16_1): b2137 - b2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. F. Grossman Community-Acquired Pneumonia: Advances in Management ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 359 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 I. I. Siempos, K. Z. Vardakas, P. Kopterides, and M. E. Falagas Adjunctive therapies for community-acquired pneumonia: a systematic review J. Antimicrob. Chemother., October 1, 2008; 62(4): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Effects of Statins and ACE Inhibitors in CAP and Influenza Journal Watch Infectious Diseases, April 2, 2008; 2008(402): 2 - 2. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |